A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19

Introduction Ropeginterferon alfa-2b is a novel mono-pegylated proline-interferon. This clinical study aimed to evaluate its antiviral efficacy of ropeginterferon alfa-2b against SARS-CoV-2 infection. Methods This is a multicenter, randomized, open-label study. Adult patients with confirmed SARS-CoV...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Infectious diseases and therapy 2024-07, Vol.13 (7), p.1575-1588
Hauptverfasser:	Liu, Wang-Da, Feng, Po-Hao, Cheng, Chien-Yu, Chou, Chun-Liang, Lee, Chih-Hsin, Lu, Min-Chi, Liu, Po-Yu, Lee, Mei-Hui, Liao, Chun-Hsing, Chen, Mei-Chuan, Chen, Cheng-Pin, Hsu, Shang-Fu, Tzeng, Yu-Tien, Lin, Yi-Chun, Ou, Tsong-Yih, Qin, Albert, Tsai, Chan-Yen, Shih, Weichung Joe, Lee, Kang-Yun, Sheng, Wang-Huei
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological response modifiers Care and treatment Clinical trial Clinical trials Coronavirus, ropeginterferon alfa-2b COVID-19 Health aspects Hospital patients Infection Infectious Diseases Infiltration Interferon Internal Medicine Medical colleges Medical research Medicine Medicine & Public Health Medicine, Experimental Original Research Proline SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 World health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Introduction Ropeginterferon alfa-2b is a novel mono-pegylated proline-interferon. This clinical study aimed to evaluate its antiviral efficacy of ropeginterferon alfa-2b against SARS-CoV-2 infection. Methods This is a multicenter, randomized, open-label study. Adult patients with confirmed SARS-CoV-2 infection with initial cycle threshold (Ct) value
ISSN:	2193-8229 2193-6382
DOI:	10.1007/s40121-024-00992-5